Does dihydromyricetin protect the kidney following ischemia–reperfusion injury in male rats?
Physiological Reports · 2025
DOI: 10.14814/phy2.70394 ↗At a glance
Journal article in Physiological Reports, 2025. Written by Fayez T Hammad and 9 co-authors. Institution: Department of Surgery, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. Major MEDLINE topics: Reperfusion Injury, Flavonols, Kidney. Cited 2 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: United Arab Emirates University (UAEU).
Abstract (original language)
Efforts to prevent the deleterious effects of the ischemia–reperfusion injury (IRI) on the kidney are ongoing. Recently, there has been an increasing interest in using natural phytochemical compounds as alternative remedies in several diseases. Dihydromyricetin is a flavonoid that is mainly extracted from some plants such as Ampelopsis grossedentata. The effect of dihydromyricetin was investigated in a rat model of renal IRI. Dihydromyricetin was dissolved in a vehicle and administered orally as a single daily dose of 400 mg/kg for 10 days prior to IRI and continued for 3 days after IRI. G‐Sham ( n = 10) underwent sham surgery, whereas G‐IRI ( n = 10) and G‐IRI/DHM ( n = 10) underwent bilateral warm renal ischemia for 35 min and received the vehicle or dihydromyricetin, respectively. Renal functions and histological changes were assessed before starting the medication, just prior to IRI, and 3 days after IRI. Dihydromyricetin significantly attenuated the alterations in serum creatinine and urea, creatinine clearance, urinary albumin, and urinary albumin creatinine ratio. Dihydromyricetin has also significantly mitigated the alterations in renal injury markers, pro‐inflammatory, pro‐fibrotic, and apoptotic cytokines, oxidative stress markers, and histological changes. We conclude that dihydromyricetin has a reno‐protective effect on the IRI‐induced renal alterations. These findings might have clinical implications.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- Department of Pathology, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- School of Medicine, University of Jordan, Amman, Jordan.
- Department of Biochemistry and Molecular Biology, College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- Al-Ahliyya Amman University, Amman, Jordan.
ORCID profiles: Fayez T Hammad
Funding
- United Arab Emirates University (UAEU)
Cite
APA
Hammad, F. T., Lubbad, L., Aljawder, M., Al Ali, A., Al-Salam, S., Hammad, A. F., Ardah, M. M., Haque, M. E., Rasheed, J. A., & Hammad, W. F. (2025). Does dihydromyricetin protect the kidney following ischemia–reperfusion injury in male rats?. Physiological Reports. https://doi.org/10.14814/phy2.70394
Vancouver
Hammad FT, Lubbad L, Aljawder M, Al Ali A, Al-Salam S, Hammad AF, et al. Does dihydromyricetin protect the kidney following ischemia–reperfusion injury in male rats?. Physiological Reports. 2025. doi:10.14814/phy2.70394
BibTeX
@article{Hammad2025,
author = {Hammad, Fayez T and Lubbad, Loay and Aljawder, Mariam and Al Ali, Azza and Al-Salam, Suhail and Hammad, Awwab F and Ardah, Mustafa M and Haque, M Emdadul and Rasheed, Jasmine Abdul and Hammad, Waheed F},
title = {Does dihydromyricetin protect the kidney following ischemia–reperfusion injury in male rats?},
journal = {Physiological Reports},
year = {2025},
doi = {10.14814/phy2.70394}
}
EUVIMED